Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
Open Access
Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study
Mafei Kang
Mafei Kang
,
Feng Xue
Feng Xue
,
Shengyuan Xu
Shengyuan Xu
,
Jieqiong Shi
Jieqiong Shi
and
Yunyan Mo
Yunyan Mo
| Jul 26, 2023
Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research Article
Published Online:
Jul 26, 2023
Page range:
405 - 410
Received:
Feb 16, 2023
Accepted:
Jun 15, 2023
DOI:
https://doi.org/10.2478/raon-2023-0036
Keywords
hepatocellular carcinoma (HCC)
,
anlotinib
,
S-1
,
molecule targeted therapy
,
chemotherapy
© 2023 Mafei Kang et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Mafei Kang
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University
Guangxi Guilin, China
Feng Xue
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University
Guangxi Guilin, China
Shengyuan Xu
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University
Guangxi Guilin, China
Jieqiong Shi
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University
Guangxi Guilin, China
Yunyan Mo
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University
Guangxi Guilin, China